LVV Platform Development

About Lentitek

Lentitek is a private, pre-revenue platform technology company addressing a critical bottleneck in the advanced therapy sector: the inefficient production of high-quality lentiviral vectors. The company's core innovation involves a novel promoter system that reduces unwanted vector genome splicing and payload breakthrough expression, leading to improved vector potency and manufacturing yields. By offering a drop-in solution compatible with both transient and stable cell line production, Lentitek aims to lower costs and improve the viability of ATMPs, including CAR-T and in-vivo gene therapies. Its mission is to enhance the scalability and accessibility of these transformative treatments.

Therapeutic Areas